Patients with atrial fibrillation who use diltiazem combined with apixaban or rivaroxaban face an increased risk for serious bleeding events compared with those who use metoprolol.

Two scores widely used to determine whether patients are at high risk for bleeding after coronary stenting disagreed in 22% of patients, and one score underestimated the risk, warned investigators ...

A new multicenter, single-arm, open-label study is the first to exclusively assess bleeding complications in patients undergoing high-risk percutaneous coronary interventions (PCI) with Impella with ...

High bleeding risk was seen among patients hospitalized with acute myocardial infarction (AMI) who had essential thrombocythemia (ET), particularly those treated with percutaneous coronary ...

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

If the novel factor XI inhibitor abelacimab reaches the market for patients with atrial fibrillation (AF) who require anticoagulation, it may not be necessary to interrupt treatment ahead of invasive ...

For patients with prostate cancer, concurrent use of enzalutamide, apalutamide, or abiraterone with DOACs does not increase risks for thrombosis or bleeding.

In patients undergoing PCI, anemia increased bleeding risk regardless of CKD status, whereas CKD by itself did not. Anemia increases the risk of bleeding in patients who have undergone percutaneous ...

Abelacimab reduces major and minor bleeding compared with rivaroxaban for atrial fibrillation -- even in patients with reduced kidney function receiving DOAC dose adjustment. Abelacimab, an ...

OCEANIC-STROKE randomized 12,327 patients within 72 hours of noncardioembolic stroke or high-risk TIA to asundexian 50 mg daily versus placebo atop single or dual antiplatelet therapy. A 26% relative ...